WilliamHSharfmanMD
Oncology • Lutherville, MDHematologic Oncology, Melanoma
Associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine Director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program.
Dr. Sharfman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
10755 Falls Rd
Lutherville, MD 21093Phone+1 410-583-2970Fax+1 410-583-2980
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1986 - 1989- Cleveland Clinic FoundationResidency, Internal Medicine, 1982 - 1985
The University of Toledo College of MedicineClass of 1982
Certifications & Licensure
DE State Medical License Current
MD State Medical License 1989 - 2025
FL State Medical License 2020 - 2022
PA State Medical License 2020 - 2022
OH State Medical License 1985 - 1990- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Start of enrollment: 1999 Feb 01
- Melanoma Biomarker Study Start of enrollment: 2006 May 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 9294 citationsSafety, activity, and immune correlates of anti-PD-1 antibody in cancer.Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27 - 2251 citationsPhase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R. Brahmer, Charles G. Drake, Ira Wollner, John D. Powderly, Joel Picus
Journal of Clinical Oncology. 2010-07-01 - 1383 citationsTumor and Microenvironment Evolution during Immunotherapy with Nivolumab.Nadeem Riaz, Jonathan J. Havel, Vladimir Makarov, Alexis Desrichard, Walter J. Urba
Cell. 2017-11-02
Journal Articles
- From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World SettingKaren B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
Miller-Coulson Academy Induction Set for April 17March 8th, 2017
Melanoma: Immunotherapy-Induced Vitiligo Documented as Linked to Better OutcomesMay 25th, 2015- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
- Member
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/william-sharfman
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
